Skip to Content

Research

NOAH

Research

Research

Clinicaltrial.gov identifier:
Status:
Closed
Scenario:
Neoadjuvant
Tumour subtype:
HER2+
Phase:
Phase III
Drug/Intervention:
Trastuzumab

Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer

Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: a randomized phase III trial with a parallel HER2-negative cohort.

IRSTCN MO16432

Collaborators

Fondazione Michelangelo

Principal investigators

José Baselga, MD, PhD

Vall d'Hebron University Hospital

Luca Gianni, MD

San Raffaele Cancer Center

Related publications

Article
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Article
urgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the neoadjuvant herceptin (NOAH) study
Article
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Congress Communications
Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH):antitumor and safety analysis.
Congress Communications
Neoadjuvant trastuzumab plus doxorubicin, paclitaxel and CMF in locally advanced breast cancer (NOAH trial): Feasibility, safety and antitumor effects
Congress Communications
Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from NOAH (neoadjuvant herceptin) phase III trial.
Congress Communications
Surgical aspect in NOAH phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer).
Congress Communications
Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial.
Congress Communications
PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer
Congress Communications
Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: gene expression analysis
Congress Communications
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer
X

En Grupo Solti utilizamos cookies, propias y de terceros, analíticas, publicitarias y de elaboración de perfiles, basadas en hábitos de navegación del usuario, para mejorar la calidad del servicio, medir la audiencia y ofrecerle publicidad que pueda ser de su interés. Puede obtener más información en nuestra Política de Cookies.

Entendemos que acepta el uso de cookies en caso de que siga navegando.

Puede gestionar las cookies y aceptarlas o rechazarlas en el Panel de Configuración.